Sunday, 20 September 2026European Markets

CNOVA Stock Rise On Tuesday, Outperforms Market

Loading stream...

(vianews) - the market ended the session with cnova (cnv.pa) rising 9.86% to €1.56 on tuesday, following the last session's downward trend. cac 40 jumped 0.23% to €7,948.40, following the last session's downward trend on what was a somewhat positive trend trading session today.

cnova's last close was €1.42, 71.43% below its 52-week high of €4.97.

about cnova

cnova n.v. operates as an e-commerce company in france and western europe. the company offers home appliances, consumer electronics, computers, home furnishings, and leisure and personal goods through its cdiscount.com website. it also operates cdiscount voyages, a travel platform; cdiscount mobile for cell phone plans; cdiscount advertising, a digital marketing solution; octopia for turnkey marketplace solutions to retailers and e-merchants; and c-logistics for transportation and logistics services. the company was founded in 1998 and is headquartered in amsterdam, the netherlands. cnova n.v. is a subsidiary of casino, guichard-perrachon s.a.

more news about cnova (cnv.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Boom Hits a Fork: Slowdown Calls Clash with Capex Confidence as Markets Get Nervous
Dario Amodei's repeated calls for a global slowdown in frontier AI development, echoed by Microsoft's new humanist AI code of conduct and FTC antitrust caution, are being publicly rejected by Nvidia and Meta leadership even as hyperscaler spending draws fresh skeptical scrutiny (Wachter's analysis, Burry-style overbuilding worries) and weak guidance from Adobe and a post-slowdown-comment selloff in GE Vernova signal investor jitters. Meanwhile wealth and security effects of the AI race keep compounding — Zhang Yiming's fortune surging on AI-driven ByteDance value, a Chinese hacking firm weaponizing AI against stolen government secrets, and low-quality AI-generated products (an AI sitcom, a spam-flooding agent platform) fueling backlash even as adoption races ahead.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,982
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,982 facts checked against source5,299 source documents archived
Query this data → isubstrate.com